Latest Security News

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Northern Minerals reports a 15% increase in its Wolverine Deposit resource and secures $28 million in funding, advancing its Browns Range heavy rare earths project amid ongoing feasibility studies.

Tasman Resources has identified six promising drill targets at its Parkinson Dam gold project in South Australia, supported by advanced geophysical analysis and a new high-resolution gravity survey. The company also highlights ongoing investment in Eden Innovations and strategic funding moves.

Tartana Minerals reports robust copper sulphate sales and completes a significant acquisition, positioning itself as a leading explorer and developer in Far North Queensland.

Breakthrough Minerals has successfully raised $500,000 through a share placement, reinforcing investor confidence and positioning the company to advance its lithium and gold projects in Australia and Canada.

Northern Minerals Limited reported a $7.56 million net cash outflow from operating activities in the December 2024 quarter, offset by $28.5 million raised through borrowings, leaving a healthy cash balance of $35.76 million.

Prescient Therapeutics has secured FDA clearance to initiate its Phase 2 PTX-100 trial for relapsed cutaneous T-cell lymphoma, alongside progress in its cell therapy platforms and a solid cash position bolstered by a recent R&D rebate.

Austin Metals Limited has reported compelling high-grade gold assay results from its Austin Gold Project, confirming significant shallow mineralisation and setting the stage for expanded drilling campaigns in 2025.

Titanium Sands Limited has made significant progress in securing its Industrial Mining License for the Mannar Project in Sri Lanka, while preparing for a crucial funding placement to support ongoing development.

Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.

Diatreme Resources has made significant strides in its silica sand ventures, signing a non-binding offtake MOU with Mitsui & Co and enhancing its leadership team. The company also reports strong cash reserves and ongoing environmental and community engagement efforts.